CAPTRUST Financial Advisors
NTLA icon

CAPTRUST Financial Advisors’s Intellia Therapeutics NTLA Stock Holding History

CAPTRUST Financial Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$288K Buy
22,465
+4,812
+27% +$61.3K ﹤0.01% 2418
2025
Q4 		$159K Buy
17,653
+6,522
+59% +$89.8K ﹤0.01% 2557
2025
Q3 		$192K Buy
+11,131
New +$137K ﹤0.01% 2440
2024
Q1 		– Sell
-12,760
Closed -$389K – 2477
2023
Q4 		$389K Sell
12,760
-6,605
-34% -$190K ﹤0.01% 1932
2023
Q3 		$612K Buy
19,365
+2,288
+13% +$88.8K ﹤0.01% 1510
2023
Q2 		$696K Buy
17,077
+3,655
+27% +$148K ﹤0.01% 1434
2023
Q1 		$500K Sell
13,422
-715
-5% -$28K ﹤0.01% 1409
2022
Q4 		$493K Sell
14,137
-103
-0.7% -$4.9K ﹤0.01% 1340
2022
Q3 		$797K Buy
14,240
+3,770
+36% +$234K ﹤0.01% 1035
2022
Q2 		$542K Sell
10,470
-2,145
-17% -$109K ﹤0.01% 1107
2022
Q1 		$917K Sell
12,615
-8,155
-39% -$691K 0.01% 883
2021
Q4 		$2.46M Buy
20,770
+3,625
+21% +$454K 0.02% 515
2021
Q3 		$2.3M Buy
17,145
+2,351
+16% +$356K 0.02% 491
2021
Q2 		$2.4M Sell
14,794
-449
-3% -$35K 0.02% 449
2021
Q1 		$1.22M Buy
15,243
+12,065
+380% +$810K 0.01% 624
2020
Q4 		$173K Buy
3,178
+2,725
+602% +$99K ﹤0.01% 1258
2020
Q3 		$9K Buy
453
+400
+755% +$8.34K ﹤0.01% 2332
2020
Q2 		$1K Buy
+53
New +$900 ﹤0.01% 2732
2018
Q4 		– Sell
-257
Closed -$7K – 1642
2018
Q3 		$7K Sell
257
-118
-31% -$3.43K ﹤0.01% 1301
2018
Q2 		$10K Buy
+375
New +$9.09K ﹤0.01% 1174

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

CAPTRUST Financial Advisors's NTLA Position: Q1 2026 in Review

CAPTRUST Financial Advisors increased its Intellia Therapeutics (NTLA) stake by 27% in Q1 2026, buying an estimated $61.3K and bringing the position to 22,465 shares worth $288K. The position accounts for ﹤0.01% of the portfolio, ranked #2418.

CAPTRUST Financial Advisors first reported a position in NTLA in Q2 2018 and has held it in 20 quarters since. The position peaked at $2.46M in Q4 2021. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • CAPTRUST Financial Advisors held 22,465 shares of Intellia Therapeutics worth $288K as of Q1 2026.
  • CAPTRUST Financial Advisors bought 4,812 Intellia Therapeutics shares in Q1 2026, an estimated $61.3K.
  • Intellia Therapeutics made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q1 2026, its #2418 holding.
  • CAPTRUST Financial Advisors first reported a position in Intellia Therapeutics in Q2 2018 and has held it in 20 quarters since.
  • CAPTRUST Financial Advisors's Intellia Therapeutics position peaked at $2.46M in Q4 2021.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q1 2026, filed 15 May 2026.